Sandra Toogood, BPharm | Authors


Targeted Therapy, Immunotherapy Propel 10 Years of Progress in NSCLC

December 01, 2022

"We should continue to see steady gains in new targets and improvements in our targeted therapies that make these options available for an ever-larger subgroup of patients with non–small cell lung cancer who can derive longer duration of benefit from additional lines of treatment," says H. Jack West, MD.